Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 2/20 | 0.61 |
| ▸ | CTSD | P07339 | 9/20 | 0.58 |
| ▸ | BACE1 | P56817 | 11/20 | 0.56 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL165644 | 1.00 | BCHE (0.61) | BCHECTSDBACE1DNM1MEN1 | |
| Hydrochloric Acid SCHEMBL5348922 | 0.99 | BCHE (0.60) | BCHECTSDBACE1DNM1MEN1 | |
| Hydrochloric Acid SCHEMBL6110582 | 0.99 | BCHE (0.60) | BCHECTSDBACE1DNM1MEN1 | |
| SCHEMBL3352016 | 0.91 | BCHE (0.51) | BCHECTSDBACE1MEN1KMT2A | |
| SCHEMBL5205801 | 0.91 | LMNA (0.54) | BCHECTSDBACE1DNM1 | |
| SCHEMBL3876015 | 0.91 | LMNA (0.54) | BCHECTSDBACE1DNM1 | |
| Hydrochloric Acid SCHEMBL5220538 | 0.90 | LMNA (0.53) | BCHECTSDBACE1DNM1 | |
| SCHEMBL4039356 | 0.89 | KDM4E (0.50) | BCHECTSDBACE1MEN1KMT2A | |
| SCHEMBL3349956 | 0.88 | BACE1 (0.57) | CTSDBACE1 | |
| SCHEMBL13409422 | 0.88 | BACE1 (0.57) | CTSDBACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7504420-B2 | Compounds which inhibit beta-secretase activity and methods of use | COMENTIS, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-20080176939-A1 | COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | COMENTIS, INC. (US) | 2008-07-24 | — | — | US | disclosed |
| EP-1871739-A1 | COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | COMENTIS, INC. (US) | 2008-01-02 | — | — | EP | disclosed |
| US-20070117793-A1 | Compounds Which Inhibit Beta-Secretase Activity and Methods of Use | ZAPAQ, INC. (US) | 2007-05-24 | — | — | US | disclosed |
| WO-2006110668-A1 | COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | COMENTIS, INC. (US) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117793-A1 | Compounds Which Inhibit Beta-Secretase Activity and Methods of Use | BACE1, BACE2, APP | BCHE 12/4885CTSD 31/4885BACE1 1/4885 |
| US-20080176939-A1 | COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | BACE1, BACE2, APP | BCHE 14/4885CTSD 50/4885BACE1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.